Hepatic
encephalopathy (HE) is a neuropsychiatric complication commonly
associated with the liver disease: cirrhosis. The inability of the
liver to metabolize ammonia results in a buildup of ammonia, which
can cross the blood–brain barrier and cause significant
neurocognitive impairment. A significant number of patients with
cirrhosis may experience HE and may be at high risk of recurrent HE.
The
severity of hepatic encephalopathy can be broadly categorized into
two classes: Covert Hepatic Encephalopathy (CHE) and Overt Hepatic
Encephalopathy (OHE). OHE is associated with high rates of mortality
and hospitalizations and poor quality of life. Factors such as
infections, gastrointestinal bleeding, metabolic disturbance, and
dietary protein overload may cause OHE. According to a study
conducted by the U.S. National Library of Medicine in 2016, 30 to 50%
of patients who have cirrhosis during their clinical care are likely
to develop OHE.
Get
Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/2596
The
global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in
2017, and is expected to witness a CAGR of 6.3% during the forecast
period (2018 – 2026).
Increasing
number of drugs in pipeline for the treatment of HE is expected to
drive the market growth during the forecast period
There
are different types of therapeutic drugs in pipeline for the
treatment of HE. Increasing number of products in pipeline for the
treatment of HE is expected to drive growth of the market over the
forecast period.
Umecrine
Cognition, a Sweden-based pharmaceutical company, is developing a
therapy that represents a new target class for several major central
nervous system (CNS)-related disorders. The lead compound GR3027 is
presently in clinical development for HE. The company plans to
demonstrate Phase II data of GR3027 for the treatment of HE in 2020.
Increasing
prevalence of various types of liver diseases is expected to aid in
the market growth
HE
is a sign of poor prognosis and correlates with mortality in both
patients with acute liver failure and those with cirrhosis associated
with end stage liver disease. Liver cirrhosis is a
gastroenterological condition that is characterized by a slow,
progressive, and irreversible replacement of liver cells by fibrous
tissue (scar) that prevents normal liver functioning.
According
to the National Center for Biotechnology Information (NCBI): 2014,
generally liver cirrhosis affects up to 1% of the U.S. and EU
population. Between 180,000 and 290,000 patients with cirrhosis in
the U.S. are hospitalized due to complications of HE. Once HE
develops, mortality reaches 22-35% after five years. HE is also
associated with increased hospitalization and treatment costs.
Moreover, subtle signs of HE are observed in around 70% of patients
with cirrhosis.
Key
Players
Key
players operating in the global hepatic encephalopathy market
include, ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V.,
Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch
Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt
Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.
Detailed
Segmentation:
Global
Hepatic Encephalopathy Market, By Drug Class:
-
Antibiotic
-
Laxatives
-
Others
Global
Hepatic Encephalopathy Market, By Distribution Channel:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Get
Full Access of This Business Report:
https://www.coherentmarketinsights.com/market-insight/hepatic-encephalopathy-market-2596
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment